Similar encouraging outcomes of chemokine-modified CAR-T cells have been demonstrated in glioblastoma (CXCR1/CXCR2) and non-small-cell lung cancer (NSCLC) (CCR2B) xenograft models [23, 24]. This evidence concerns the gene CCR2 and non-small cell lung carcinoma.